title: The Efficacy of Taxanes- and Oxaliplatin-Based Chemotherapy in the Treatment of Gastric Cancer After D2 Gastrectomy for Different Lauren Types.
abstract: To investigate the efficacy of Taxanes- and Oxaliplatin-based chemotherapies (TC and OC) in the treatment of gastric cancer patients after D2 gastrectomy with different Lauren types. In this study, 299 patients of gastric adenocarcinoma with D2 lymph node dissection were reviewed between 2007 and 2014. Chemotherapies were classified as Oxaliplatin-based and Taxanes-based regimen. Treatment outcomes were analyzed according to different Lauren types, such as the intestinal type, diffuse type, and mixed type groups, respectively. The disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The log-rank test was used for univariate analysis, and Cox regression was used for multivariate analysis. In diffuse type gastric cancer, the Oxaliplatin-based arm had a longer median DFS and OS compared with Taxanes-based arm (DFS: 47.0 vs 28.6 months, P = 0.04; OS: 51.9 vs 34.5 months, P = 0.048). The chemotherapy regimen was an independent prognostic factor for DFS and OS of diffuse type gastric cancer patients by multivariate analysis (P = 0.01). In the intestinal type, although the DFS and OS of intestinal type patients in TC group were higher than those in OC group (DFS: 53.4 vs 42.4 months; OS: 69.7 vs 57.8 months), there was no statistical significance observed (both P > 0.05). For the mixed type, the 2 different chemotherapy regimens achieved similar median DFS and OS. In a conclusion, the patients of diffuse type were more sensitive to OC, and the intestinal type patients may be benefit from TC. Therefore, it will be of benefit for gastric patients by introducing Lauren classification clinically and to help the choice of chemotherapy regimen for gastric patients after D2 gastrectomy.
authors.affiliation: From the Departments of Radiotherapy and Chemotherapy (ZZ, XJ, BL, HS, HC, SF, ZF, HP, CX), Pathology (QH, GC), and Gastrointestinal Surgery (XC), The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, P.R. China.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Zheng
authors.forename: Xiance
authors.initials: X
authors.lastname: Jin
authors.forename: Qiuxiang
authors.initials: Q
authors.lastname: He
authors.forename: Baochai
authors.initials: B
authors.lastname: Lin
authors.forename: Huafang
authors.initials: H
authors.lastname: Su
authors.forename: Hanbin
authors.initials: H
authors.lastname: Chen
authors.forename: Shaoran
authors.initials: S
authors.lastname: Fei
authors.forename: Zhenghua
authors.initials: Z
authors.lastname: Fei
authors.forename: Guorong
authors.initials: G
authors.lastname: Chen
authors.forename: Huangle
authors.initials: H
authors.lastname: Pan
authors.forename: Xiaolei
authors.initials: X
authors.lastname: Chen
authors.forename: Congying
authors.initials: C
authors.lastname: Xie
mesh_terms: D000230:Adenocarcinoma / Q000145:classification* / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D000077150:Oxaliplatin; D011184:Postoperative Period; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000145:classification* / Q000628:therapy*; D043823:Taxoids / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D043823:Taxoids; D000077150:Oxaliplatin